ALLO – allogene therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Allogene Therapeutics Announces Participation in December Investor Conferences
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at William Blair.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an "overweight" rating on the stock.
Form 8-K Allogene Therapeutics, For: Nov 11
Form SC 13G/A Allogene Therapeutics, Filed by: VANGUARD GROUP INC
Form SC 13G/A Allogene Therapeutics, Filed by: BlackRock, Inc.
Form 10-Q Allogene Therapeutics, For: Sep 30
Form 8-K Allogene Therapeutics, For: Nov 07
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.